tucatinib,trastuzumab
seagen
the results of the mountaineer phase 2 trial are presented at #wcgic2022. rasw/her2+ chemorefractory mcrc,
tucatinib+trastuzumab pfs: 8.2 m os: 24.1 m although her2 positivity is rare in crc, it is certain that it will change practice in this population. 
Medical Oncologist